Lundbeck Reveals Promising Phase 1b Results for Parkinson's Treatment at AD/PD™ 2026 New Phase 1b data on Lu AF28996 presented by Lundbeck reveals promising results for advanced Parkinson's disease treatment at AD/PD™ 2026.

Lundbeck Reveals Promising Phase 1b Results for Parkinson's Treatment at AD/PD™ 2026 #Denmark #Copenhagen #Parkinson's #Lundbeck #Lu_AF28996

Lundbeck Showcases Promising Phase 1b Data for Parkinson's Treatment at AD/PD™ 2026 Lundbeck has unveiled promising Phase 1b data for Lu AF28996—an innovative treatment for advanced Parkinson's disease—set to be shared at AD/PD™ 2026.

Lundbeck Showcases Promising Phase 1b Data for Parkinson's Treatment at AD/PD™ 2026 #Denmark #Copenhagen #Parkinson's #Lundbeck #Lu_AF28996

Lundbeck names AI head in quest to become 'bionic' company Lundbeck has appointed Markus Kede to the newly created role of chief AI officer, charged with driving its ambition to become a 'bionic' company.

Danish pharmaceutical company #Lundbeck has appointed #MarkusKede to the role of #chiefAIofficer (CAO), promoting him from the role of head of finance and business planning.

Lundbeck Accelerates AI Integration by Appointing New Chief AI Officer Lundbeck has appointed Markus Kede as the Chief AI Officer, advancing its commitment to integrating AI for innovative solutions in healthcare.

Lundbeck Accelerates AI Integration by Appointing New Chief AI Officer #Denmark #AI_Strategy #Lundbeck #Valby #Markus_Kede

Lundbeck Appoints Markus Kede as Their New Chief AI Officer Markus Kede has been appointed as the Chief AI Officer at Lundbeck, marking a pivotal move towards becoming a bionic company driven by AI.

Lundbeck Appoints Markus Kede as Their New Chief AI Officer #Denmark #Lundbeck #Chief_AI_Officer #Valby #Markus_Kede

Takeda signs $1.7bn AI alliance with Iambic Iambic bags another pharma partner, Takeda, which plans to use its AI platform to find drugs for cancer, gastrointestinal, and inflammatory disorders

#Takeda #AIalliance #AI #IambicTherapeutics #drugdiscovery #inflammatorydiseases #oncology #NeuralPLexer #smallmoleculetherapeutics #RevolutionMedicines #neurology #Lundbeck #NablaBio #Arzeda #nference #CytoReason #AIStructuralBiology #AISBconsortium #OpenFoldstructure
zurl.co/wMIRf

#Lundbeck seems to have brought its #migraine prevention drug bocunebart back on track, after dropping development of one formulation of the #antiPACAP antibody last year.

buff.ly/LH6HI78

Lundbeck preps phase 3 for migraine prevention drug Lundbeck seems to have brought its migraine prevention drug bocunebart back on track with positive data for an intravenous formulation.

#Lundbeck #phase3 #migraineprevention #migrainepreventiondrug #bocunebart #antiPACAPantibody #phase2b #PROCEEDtrial #intravenousbocunebart #LuAG09222 #monthlymigrainedays #MMD #PACAP #neuropeptide #pathophysiologyofmigraine #migrainetreatment #PACAPpathway #migrainepreventionmarket
zurl.co/M7FHE

Strong performance in the US has driven Lundbeck to record 2025 results. Revenue increased 13% to DKK 24,630 million, while strategic brands grew to represent 77% of total sales. Adjusted EBITDA rose 24%. #Lundbeck #LifeScience

Lundbeck's Latest Research Shows Significant Migraine Relief with Vyepti® in Real-World Settings New data from Lundbeck's INFUSE study demonstrates that Vyepti® leads to substantial improvements in migraine patients' conditions, presented at the HCOP Annual Conference.

Lundbeck's Latest Research Shows Significant Migraine Relief with Vyepti® in Real-World Settings #USA #Lundbeck #Ojai #Migraine #Vyepti

Lundbeck's Bexicaserin Shows Long-Term Efficacy for Childhood Epilepsies at AES 2025 Lundbeck revealed promising long-term data for bexicaserin, an investigational treatment for childhood-onset epilepsies, showing significant seizure reduction and safety.

Lundbeck's Bexicaserin Shows Long-Term Efficacy for Childhood Epilepsies at AES 2025 #Denmark #Lundbeck #bexicaserin #Valby #DEEs

Lundbeck Unveils Encouraging Phase 2 Data for Bexicaserin in Rare Childhood Epilepsies at AES 2025 Lundbeck reveals new long-term outcomes for bexicaserin, showing sustained reduction in seizure frequency in rare childhood-onset epilepsies during AES 2025.

Lundbeck Unveils Encouraging Phase 2 Data for Bexicaserin in Rare Childhood Epilepsies at AES 2025 #Denmark #Epilepsy #Lundbeck #bexicaserin #Valby

Lundbeck Unveils Promising New Data on Bexicaserin at American Epilepsy Society Meeting Lundbeck's latest findings on bexicaserin show hope for treating rare childhood-onset epilepsies, highlighting early seizure reductions and long-term efficacy.

Lundbeck Unveils Promising New Data on Bexicaserin at American Epilepsy Society Meeting #Denmark #Epilepsy #Lundbeck #bexicaserin #Valby

Lundbeck Unveils New Bexicaserin Data for Childhood Epilepsies at AES 2025 At the AES 2025 Annual Meeting, Lundbeck introduces promising data on Bexicaserin for treating seizures in childhood epilepsy, showing early and sustained effects.

Lundbeck Unveils New Bexicaserin Data for Childhood Epilepsies at AES 2025 #USA #Atlanta #Lundbeck #bexicaserin #DEEs

Lundbeck bows out of bidding war for Avadel Lundbeck won't raise its offer to buy Avadel any further, clearing the way for the sleep disorder specialist to complete a merger with Alkermes.

#Lundbeck has said it won't raise its offer to buy #AvadelPharma any further, clearing the way for the sleep disorder specialist to complete a #merger with #Alkermes.

pharmaphorum.com/news/lundbec...

Alkermes offers more for Avadel after Lundbeck bid Alkermes has been forced to raise its offer for narcolepsy drug developer Avadel Pharma, after a rival bid from Lundbeck was deemed superior.

#Alkermes has been forced to raise its offer for #narcolepsy drug developer #AvadelPharma, after a rival bid from #Lundbeck was deemed superior.

Lundbeck makes bid for Avadel, trying to displace Alkermes Another pharma M&A fight has broken out, with Lundbeck outbidding Alkermes in an attempt to take control of Avadel Pharma and its narcolepsy product.

Another pharma M&A fight has broken out, with #Lundbeck outbidding #Alkermes in an attempt to take control of #AvadelPharma and its approved therapy for the sleep disorder #narcolepsy.

Pharmalittle: We're reading about a Merck acquisition, Novo facing shareholder backlash, and more Merck agreed to buy Cidara Therapeutics, the maker of an experimental flu therapy, in a $9.2 billion deal

Pharmalot.. Pharmalittle.. Good Morning: We’re reading about a Merck acquisition, Novo facing shareholder backlash, and more news.. statnews.com/pharmalot/20... #pharma #flu #opioids #Merck #NovoNordisk #JNJ #BristolMyers #Lundbeck #Alkermes #Cidara

Alkermes Analyzes Avadel's Announcement Regarding Potential Acquisition Alkermes assesses Avadel Pharmaceuticals' recent announcement about a potential acquisition offer from H. Lundbeck A/S, revealing strategic considerations.

Alkermes Analyzes Avadel's Announcement Regarding Potential Acquisition #USA #Dublin #Lundbeck #Alkermes #Avadel

Alkermes Responds to Avadel's Potential Acquisition Offer by Lundbeck Alkermes plc has acknowledged Avadel Pharmaceuticals' recent announcement concerning a potential acquisition bid from Lundbeck, evaluating its options.

Alkermes Responds to Avadel's Potential Acquisition Offer by Lundbeck #USA #Dublin #Lundbeck #Alkermes #Avadel

Lundbeck Seeks Approval for Vyepti® in Asian Countries to Treat Migraines Lundbeck has submitted a new drug application for Vyepti® in Japan, China, and South Korea, aiming to enhance treatment options for migraine sufferers.

Lundbeck Seeks Approval for Vyepti® in Asian Countries to Treat Migraines #Japan #Lundbeck #Valby #Vyepti #Eptinezumab

Lundbeck Posts 14% Revenue Growth on the Strength of Vyepti and Rexulti Lundbeck has reported a significant 14% growth in revenue for the first nine months of 2025, led by robust sales of Vyepti and Rexulti, fueled by strategic investments.

Lundbeck Posts 14% Revenue Growth on the Strength of Vyepti and Rexulti #Denmark #Lundbeck #Valby #Vyepti #Rexulti

Lundbeck Reports 14% Revenue Growth Driven by Key Strategic Medications Vyepti® and Rexulti® Lundbeck showcases impressive 14% revenue growth fueled by strategic investments in Vyepti® and Rexulti®. This article dives into the details of their financial performance and future outlook.

Lundbeck Reports 14% Revenue Growth Driven by Key Strategic Medications Vyepti® and Rexulti® #Denmark #Lundbeck #Valby #Vyepti #Rexulti

Lundbeck's Bexicaserin Gains Breakthrough Therapy Status in China for Severe Epilepsies Lundbeck's investigational drug Bexicaserin has been granted Breakthrough Therapy Designation in China for treating severe rare epilepsies, highlighting urgent patient needs.

Lundbeck's Bexicaserin Gains Breakthrough Therapy Status in China for Severe Epilepsies #China #Lundbeck #bexicaserin #Valby #Developmental_Epileptic_Encephalopathies

Lundbeck Reveals Pioneering Trial Design for Amlenetug at 2025 Movement Disorders Congress At the 2025 Congress, Lundbeck will present its innovative Phase 3 trial for Amlenetug aimed at treating Multiple System Atrophy, addressing significant patient needs.

Lundbeck Reveals Pioneering Trial Design for Amlenetug at 2025 Movement Disorders Congress #USA #Honolulu #Lundbeck #MSA #Amlenetug

Lundbeck to Present Phase 3 MASCOT Trial Design for MSA at International Congress in 2025 Lundbeck will reveal the innovative Phase 3 MASCOT trial design for amlenetug in treating Multiple System Atrophy at the upcoming congress.

Lundbeck to Present Phase 3 MASCOT Trial Design for MSA at International Congress in 2025 #Denmark #Lundbeck #Valby #Amlenetug #mascot

Lundbeck unveils migraine data for eptinezumab at international congress - PharmaTimes New phase 4 results show sustained symptom relief and improved patient outcomes

#neurology #drugdevelopment #Lundbeck #migraine #eptinezumab #migarinesymptomrelief #patientoutcomes #InternationalHeadacheCongress #migrainepatients #chronicmigraine #RESOLUTIONclinicaltrial #SUNSETclinicaltrial #medicationoveruseheadache #monthlymigrainedays #MMDs
zurl.co/LE6FP

New CEO to slash 9,000 jobs at Novo Nordisk in restructure Novo Nordisk will cut 9,000 jobs across the company as it reallocates resources toward growth and innovation in the obesity and diabetes markets.

#NovoNordisk #restructure #MikeDoustdar #obesity #diabetes #chronicdiseases #restructuring #obesitydrugs #EliLilly #drugcompounders #greymarketproviders #staffcuts #Moderna #Bayer #MSD #Iovance #CSL #Lundbeck #MostFavouredNationsdrugpricingscheme #tariffs #patentexpirations
zurl.co/Imo5i

Lundbeck unveils migraine data for eptinezumab at international congress - PharmaTimes New phase 4 results show sustained symptom relief and improved patient outcomes

#neurology #drugdevelopment #Lundbeck #migraine #eptinezumab #migarinesymptomrelief #patientoutcomes #InternationalHeadacheCongress #migrainepatients #chronicmigraine #RESOLUTIONclinicaltrial #SUNSETclinicaltrial #medicationoveruseheadache #monthlymigrainedays #MMDs
zurl.co/HStkM

Lundbeck Reveals New Migraine Clinical Data at IHC 2025: Eptinezumab Effects and More Lundbeck showcases significant migraine data at the 2025 International Headache Congress, highlighting the long-term effectiveness of Eptinezumab in chronic migraine patients, aiming to improve lives.

Lundbeck Reveals New Migraine Clinical Data at IHC 2025: Eptinezumab Effects and More #United_States #São_Paulo #Lundbeck #Vyepti #Eptinezumab